Introduction {#Sec1}
============

PEMFs have been used for many years \[[@CR44]\]. They reportedly are effective for treating nonunions \[[@CR1], [@CR7], [@CR10]\], delayed unions \[[@CR1], [@CR42], [@CR44]\], osteotomies \[[@CR32]\], avascular necrosis of the femoral head \[[@CR5], [@CR34]\], bone grafts \[[@CR11]\], and spinal fusion \[[@CR36]\]. Although the therapeutic properties of PEMFs are well known, the sequence of events by which electromagnetic stimulation can bring about its desirable effects on bone healing is not completely understood. PEMFs modify some important physiologic parameters of cells, such as proliferation, transduction, transcription, synthesis, and secretion of growth factors \[[@CR24]\]. PEMFs induce cell proliferation in mitogen-stimulated lymphocytes \[[@CR10]\] and improve IL-2 receptor expression and IL-2 use in lymphocytes from aged donors, which are characterized by defective production and use of this growth factor \[[@CR10]\]. PEMF exposure induces cell proliferation in human osteoblasts and chondrocytes cultured in vitro \[[@CR18], [@CR20], [@CR38], [@CR44], [@CR45]\]. PEMFs determine signal transduction by means of intracellular release of Ca^2+^ leading to an increase in cytosolic Ca^2+^ and an increase in activated cytoskeletal calmodulin \[[@CR9]\]. PEMFs induce a dose-dependent increase in bone \[[@CR2]\] and cartilage differentiation \[[@CR2]--[@CR4], [@CR33]\], and upregulation of mRNA expression of extracellular matrix molecules, proteoglycan, and Type II collagen \[[@CR3]\]. The acceleration of chondrogenic differentiation is associated with increased expression of TGF-β1 mRNA and protein \[[@CR4]\], suggesting the stimulation of TGF-β1 may be a mechanism through which PEMFs affect complex tissue behavior such as cell differentiation and through which the effects of PEMFs may be amplified \[[@CR4]\]. PEMFs also are postulated to act at a membrane level influencing signal transduction of several hormones or growth factors such as parathyroid hormone, IGF 2, and adenosine A2a, producing the amplification of their transmembrane receptors \[[@CR1], [@CR19], [@CR21], [@CR23], [@CR31], [@CR46]\]. Studies of single genes using RT-PCR suggest activation of osteocalcin, osteopontin, and TGF-β transcription during osteogenesis \[[@CR22]\] and inhibition of cyclooxygenase 2 in synovial fibroblasts stimulated with TNFα or lipopolysaccharide \[[@CR21]\]. A wide analysis of gene expression in cells exposed to PEMFs has not been performed: most studies focus on a few aspects of cell activities or they have been performed using different types of signals in different experimental conditions.

We therefore asked (1) whether PEMFs affected a wide array of genes in human osteoblastlike cells (MG63), and (2) whether and to what extent PEMFs induce proliferation and differentiation of osteoblasts.

Materials and Methods {#Sec2}
=====================

We treated osteoblastlike cell cultures (MG-63) with PEMFs for 18 hours, and maintained similar nontreated controls. Gene expression of both groups therefore was evaluated with cDNA microarray analysis, containing 19,000 genes spanning a substantial fraction of the human genome. All experiments were performed in triplicate in the same culture conditions for control and treated cells.

Osteoblastlike cells (MG63) were grown in sterile Falcon wells (Becton & Dickinson, Franklin Lakes, NJ) containing Eagle's minimum essential medium supplemented with 10% fetal calf serum (Sigma-Aldrich, St Louis, MO) and antibiotics (penicillin 100 U/mL and streptomycin 100 μg/mL; Sigma-Aldrich). Cultures were maintained in a 5% CO~2~ humidified atmosphere at 37°C. For the assay, cells were collected and seeded at a density of 1 × 10^5^ cells/mL in two multiwells (one for the control and one for the treated). Each multiwell was comprised of six wells, 9-cm^2^, in which 3-mL of complete medium was added.

After 24 hours, cells were exposed to PEMFs for 18 hours using a PEMF generator system (Igea, Carpi, Italy). The PEMF used in this study is used clinically to treat nonunions or delayed unions and avascular necrosis of the femoral head \[[@CR32]--[@CR34]\]. The solenoids were powered using a Biostim pulse generator (Igea), a PEMF generator. The electromagnetic bioreactor applied to the cells has the following characteristics: intensity of the magnetic field, 2 ± 0.2 mT; amplitude of the induced electric tension, 5 ± 1 mV; signal frequency, 75 ± 2 Hz; and pulse duration, 1.3 ms. The stimulated multiwell was placed parallel between the two solenoids of the PEMF generator. The solenoids were placed at a distance of 10 cm and the multiwell was located on an acrylic support exactly at the center of the two solenoids. Control cultures were placed in the same incubator; nevertheless, the presence of the electromagnetic field was checked and its value was less than 0.05 mT. This value was ineffective in previous studies \[[@CR38]--[@CR46]\]. After 18 hours, when cultures were subconfluent, cells were processed for RNA extraction.

For DNA microarray screening and analysis, we used the same protocol as described previously \[[@CR12]--[@CR16]\]. Briefly, RNA was extracted from cells by using RNAzol. Ten micrograms of total RNA was used for each sample. cDNA was synthesized by using Superscript II (Life Technologies, Invitrogen, Milano, Italy) and amino-allyl dUTP (Sigma-Aldrich). Monoreactive Cy3 and Cy5 esters (Amersham Pharmacia, Little Chalfont, UK) were used for indirect cDNA labeling. RNA extracted from untreated cells was labeled with Cy3 and used as control against the Cy5-labeled treated (PG) cDNA in the first experiment and then switched. For 20 K human DNA microarrays slides (MWG Biotech AG, Ebersberg, Germany), 100 μL of the sample and control cDNAs in DIG Easy hybridization solution (Roche, Basel, Switzerland) were used in a sandwich hybridization of the two slides, constituting the 20 K set at 37°C overnight. Washing was performed three times for 10 minutes with 1× saline sodium citrate (SSC) and 0.1% sodium dodecyl sulfate at 42°C and three times for 5 minutes with 0.1× SSC at room temperature. Slides were dried by centrifugation for 2 minutes at 2000 rpm. Hybridized arrays were scanned with a GenePix 4000 scanner (Axon Instruments) at variable photomultiplier tube (PMT) voltage to obtain maximal signal intensities with less than 1% probe saturation.

The Foreground Median intensity for Cy3 and Cy5, Background Median intensity for Cy3 and Cy5, spot size data were imported into BRB-ArrayTools software \[[@CR43]\] using the Import wizard function. Global normalization was used to median center the log-ratios on each array r to adjust for differences in labeling intensities of the Cy3 and Cy5 dyes.

The normalized Log ratios also were imported to Significance Analysis of Microarray (SAM) \[[@CR48]\] software to identify differentially expressed genes. SAM assigns a score to each gene on the basis of a change in gene expression relative to the standard deviation of repeated measurements. For genes with scores greater than an adjustable threshold, SAM uses permutations of the repeated measurements to estimate the percentage of genes identified by chance---the false discovery rate (FDR). Analysis parameters (Delta) were set to result in zero FDR.

Results {#Sec3}
=======

PEMF affected gene expression in MG-63 osteoblastlike cells (Fig. [1](#Fig1){ref-type="fig"}). The genes differentially expressed in cells treated with PEMFs were either upregulated (268 genes) (Table [1](#Tab1){ref-type="table"}) or downregulated (277 genes) (Table [2](#Tab2){ref-type="table"}). PEMF induced osteoblast proliferation and differentiation and regulated genes involved in bone formation in the direction of an enhancement of osteogenesis (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).Fig. 1A microarray (SAM) plot of MG63 exposed to PEMFs versus control is shown. Expected differentially expressed genes are reported on the x axis, whereas observed differentially expressed genes are reported on the y axis. Downregulated genes (green) are located in the lower left of the graph; upregulated genes (red) are in the upper right; genes with different expression but statistically insignificant are shown in black. Parallel lines drawn from the lower left to upper right squares are the cutoff limits. The solid line indicates the equal value of observed and expected differentially expressed genes.Table 1Upregulated genesGenBankNameSymbolCytobandScore (d)\*W19447DEAD (Asp-Glu-Ala-Asp) box polypeptide 51DDX5112q24.3345.15BM908669Glyceraldehyde-3-phosphate dehydrogenaseGAPDH12p1342.40W33064Tubulin, alpha 4aTUBA4A2q3540.89BI258438Cofilin 1 (nonmuscle)CFL111q1339.61H80610Hypothetical protein LOC729176LOC7291766q24.335.42R23641Vacuolar protein sorting 13 homolog AVPS13A9q2132.28BM006748Enolase 1 (alpha)ENO11p36.3-p36.231.99W44826Major histocompatibility complex, class I, EHLA-E6p21.331.04BG547115Ferritin, heavy polypeptide 1FTH111q1330.55BG288116Integrin, alpha 2ITGA25q23-q3127.14BQ014343Family with sequence similarity 62FAM62B7q36.326.05R89805ELOVL family member 7ELOVL75q12.125.81BQ108591Ribosomal protein S5RPS519q13.425.71H61302Hexose-6-phosphate dehydrogenaseH6PD1p3625.10AA151568Testis enhanced gene transcript (BAX inhibitor 1)TEGT12q12-q1324.95H30300Small nuclear ribonucleoprotein polypeptide NSNRPN15q11.224.75N72456Similar to RIKEN cDNA A730055C05 geneLOC38833517p13.124.38H25618Chromatin modifying protein 5CHMP59p13.324.12AA059376Similar to phosphodiesterase 4D interacting protein isoform 2LOC6535131q21.124.01W30787DnaJ (Hsp40) homolog, subfamily C, member 15DNAJC1513q14.124.00BM801770Solute carrier family 35, member E3SLC35E312q1523.64AA099240NIPA-like domain containing 3NPAL31p36.12-p35.123.55W00391Solute carrier family 11 member 2SLC11A212q1323.36H12528Annexin A5ANXA54q26-q28\|4q28-q3223.13N54759Prenylcysteine oxidase 1PCYOX12p13.323.08T89646ST3 beta-galactoside alpha-2,3-sialyltransferase 2ST3GAL216q22.122.82AA029517KCNQ1 overlapping transcript 1KCNQ1OT111p1522.75W47664NAD(P)H dehydrogenase, quinone 1NQO116q22.122.73W02597PMS1 postmeiotic segregation increased 1PMS12q31-q33\|2q31.122.61R11416Seryl-tRNA synthetaseSARS1p13.3-p13.122.55H67332GTP binding protein 1GTPBP122q13.122.43H86020NADH dehydrogenaseNDUFB53q26.3322.21AA031564Chromosome 1 open reading frame 212C1orf2121p34.321.90W67485Zinc finger protein 136ZNF13619p13.2-p13.1221.68W32906Zinc finger protein 702ZNF70219q13.4121.49BI492783Zinc finger protein 207ZNF20717q11.221.43BE278092Ribosomal protein L10RPL10Xq2821.42N90960Par-6 partitioning defective 6 homolog betaPARD6B20q13.1321.32BG565169Ferritin, light polypeptideFTL19q13.3-q13.421.29H75902Complement component (3b/4b) receptor 1CR11q3221.15W31736NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDaNDUFV111q1320.96AA417686Casein kinase 1, gamma 3CSNK1G35q2320.94R18627Amyloid beta precursor protein binding protein 2APPBP217q21-q2320.81W38809Kelch-like 8 (Drosophila)KLHL84q22.120.76BM456402Hypothetical gene LOC96610LOC9661022q11.2220.70AA044942Eukaryotic translation initiation factor 4 gamma, 1EIF4G13q27-qter20.44BM041235Actin, alpha 2, smooth muscle, aortaACTA210q23.320.42AI690073Glutamate-cysteine ligase, catalytic subunitGCLC6p1220.30AI734239Coiled-coil domain containing 120CCDC120Xp11.2320.28N72922PDZ and LIM domain 5PDLIM54q2220.23N50768Chromosome X open reading frame 57CXorf57Xq22.320.05N76504Hypothetical protein LOC257407LOC2574072q37.119.69N45145Zinc finger, CCHC domain containing 4ZCCHC44p15.219.60BM922198Tubulin, beta 2CTUBB2C9q3419.57H65175Solute carrier family 31 (copper transporters), member 1SLC31A19q31-q3219.50H83172Cytochrome b5 domain containing 2CYB5D217p13.219.28N73208Zinc finger protein 207ZNF20717q11.219.26H95413Hydroxysteroid (17-beta) dehydrogenase 7HSD17B71q2319.21N72546Cathepsin SCTSS1q2119.08BM705000Cold shock domain protein ACSDA12p13.119.08W86495Coiled-coil-helix-coiled-coil-helix domain containing 7CHCHD78q12.119.07BI092679H19, imprinted maternally expressed untranslated mRNAH1911p15.518.99N45602Serine/threonine kinase 4STK420q11.2-q13.218.93H78769Interleukin-1 receptor-associated kinase 4IRAK412q1218.88W35195Lethal giant larvae homolog 1 (Drosophila)LLGL117p11.218.88AA062617Myotubularin related protein 9MTMR98p23-p2218.85BE315195Ribosomal protein L8RPL88q24.318.84BQ067508Glyceraldehyde-3-phosphate dehydrogenaseGAPDH12p1318.76R35530RAD23 homolog B (S cerevisiae)RAD23B9q31.218.75H24644AlkB, alkylation repair homolog 5 (E coli)ALKBH517p11.218.57BM010025Signal transducer and activator of transcription 3STAT317q21.3118.53H08490Chloride channel 2CLCN23q27-q2818.39H80175RadixinRDX11q2318.27H46045Tripartite motif-containing 46TRIM461q2218.18N25456Mutated in colorectal cancersMCC5q2118.07AA047157CD82 moleculeCD8211p11.218.01AA044701ADAMTS-like 5ADAMTSL519p13.317.82BM477950Ribosomal protein L8RPL88q24.317.79AI587328Radical S-adenosyl methionine domain containing 2RSAD22p25.217.68W03282Dihydrofolate reductaseDHFR5q11.2-q13.217.62BQ072807Ribosomal protein L13aRPL13A19q13.317.52H01638Coiled-coil domain containing 82CCDC8211q2117.48BG529617Ribosomal protein, large, P1RPLP115q2217.45H63198RAB interacting factorRABIF1q32-q4117.34BG397205Proteasome (prosome, macropain) subunit, beta type, 4PSMB41q2117.33W31052Nephronophthisis 3 (adolescent)NPHP33q22.117.26BM925268Chromosome 12 open reading frame 32C12orf3212p13.3317.25H83233Malate dehydrogenase 1, NAD (soluble)MDH12p13.317.23W19108UBX domain containing 4UBXD42p23.317.22AA004532Fusion (involved in t(12;16) in malignant liposarcoma)FUS16p11.217.21R50299SHANK-associated RH domain interactorSHARPIN8q24.317.01R47837Zinc finger, RAN-binding domain containing 2ZRANB21p3116.99H85307V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologKRAS12p12.116.89N49567Agmatine ureohydrolase (agmatinase)AGMAT1p36.2116.88N57076KIAA1909 proteinKIAA19095p15.3316.84BI116974Ribosomal protein L18RPL1819q1316.83N40643Chromosome 10 open reading frame 18C10orf1810p15.116.74R82575KIAA1704KIAA170413q13-q1416.51BI196362Tubulin, alpha 1aTUBA1A12q12-q14.316.36AA132192Pleckstrin homology domain containing, family H member 2PLEKHH22p2116.34N31221Hypothetical protein DKFZp667M2411DKFZp667M241117q11.216.31H45243GDNF-inducible zinc finger protein 1GZF120p12.3-p11.2116.29T86807Serine/threonine kinase 19STK196p21.316.28AA057270Choline kinase alphaCHKA11q13.216.20R66209Synaptosomal-associated protein, 29 kDaSNAP2922q11.2116.13R92306DnaJ (Hsp40) homolog, subfamily C, member 19DNAJC193q26.3316.13T80698Glycine-N-acyltransferase-like 1GLYATL111q12.116.12N42722Guanine nucleotide binding protein (G protein), gamma 12GNG121p31.316.03BM911128Secreted protein, acidic, cysteine-rich (osteonectin)SPARC5q31.3-q3215.99N34619Coagulation factor II (thrombin) receptor-like 2F2RL25q1315.97AA039528C-Maf-inducing proteinCMIP16q2315.76N53715Neural precursor cell expressedNEDD814q1215.75BQ055308Ribosomal protein L4RPL415q2215.73N44567Torsin A interacting protein 1TOR1AIP11q24.215.63AA046698Selenoprotein ISELI2p23.315.62T75376Notch homolog 2 (Drosophila)NOTCH21p13-p1115.49N46675Unkempt homolog (Drosophila)UNK17q25.115.44R93756Calmodulin 1 (phosphorylase kinase, delta)CALM114q24-q3115.42R67177Adenylate cyclase 1 (brain)ADCY17p13-p1215.39W24597Deoxyribonuclease II, lysosomalDNASE219p13.215.28H43825HLA-B associated transcript 2BAT26p21.315.26N20577Leucine rich repeat containing 57LRRC5715q15.115.24BI598074Neugrin, neurite outgrowth associatedNGRN15q26.115.23W79562Arginyltransferase 1ATE110q26.1315.20R68004Poly(rC) binding protein 2PCBP212q13.12-q13.1315.19AA040826Major histocompatibility complex, class I, CHLA-C6p21.315.12H52744Abhydrolase domain containing 12ABHD1220p11.2115.11N78350RAN binding protein 1RANBP122q11.2115.10BQ026918Collagen, type I, alpha 2COL1A27q22.115.05BG109286COX18 cytochrome c oxidase assembly homologCOX184q13.315.02W47525Trans-golgi network protein 2TGOLN22p11.215.02BI494911Nck-associated protein 5NAP52q21.214.89N94192Glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)GNS12q1414.84N28281Zinc finger protein 552ZNF55219q13.4314.61R84726Adenosine A1 receptorADORA11q32.114.59W40304Apoptosis inhibitor 5API511p11.214.54W63760CoilinCOIL17q22-q2314.52T97408BCL2-associated athanogeneBAG19p1214.51BM923884Glutathione S-transferase piGSTP111q1314.49N46186Glutaredoxin 5 homolog (S cerevisiae)GLRX514q32.1314.40N57438Vitamin K epoxide reductase complex, subunit 1-like 1VKORC1L17q11.2114.38W19461Abl interactor 2ABI22q3314.33R74572Serine incorporator 1SERINC16q22.3114.24N28330Melanoma cell adhesion moleculeMCAM11q23.314.23N20611GTP-binding protein 10 (putative)GTPBP107q21.1314.23H74119Sec61 beta subunitSEC61B9q22.32-q31.314.13N52748Zinc finger protein 536ZNF53619q1214.13R48809Hypothetical gene supported by AK123662LOC3886921q21.114.13AA005393NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDaNDUFV218p11.31-p11.214.12R89913CD58 moleculeCD581p1314.08W03395Elongation of very long chain fatty acids-like 1ELOVL11p34.213.97BM541374Peptidylprolyl isomerase H (cyclophilin H)PPIH1p34.113.96AA046918Splicing factor 3b, subunit 2, 145 kDaSF3B211q13.113.95R60604TAF5-like RNA polymerase IITAF5L1q42.1313.89H39844Small nuclear RNA activating complex, polypeptide 3SNAPC39p22.313.84N39630Purinergic receptor P2X, ligand-gated ion channel, 7P2RX712q2413.82H57205VinculinVCL10q22.1-q2313.77N39274Hook homolog 3 (Drosophila)HOOK38p11.2113.74H14054Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)B3GAT311q12.313.59BG676419Potassium channel tetramerisation domain containing 13KCTD1316p11.213.59N31020Similar to Signal peptidase complex subunit 2LOC6535661p35.313.57BG110260FK506 binding protein 14, 22 kDaFKBP147p15.113.56H53224Transferrin receptor (p90, CD71)TFRC3q2913.54R31353Glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)GNS12q1413.51AA128133Nexilin (F actin binding protein)NEXN1p31.113.49BQ070812Proteasome (prosome, macropain) 26S subunit, ATPase, 3PSMC311p12-p1313.48H94761Disrupted in schizophrenia 1DISC11q42.113.48BQ050099Ras homolog gene family, member ARHOA3p21.313.39BG169474UTP14, U3 small nucleolar ribonucleoproteinUTP14AXq2513.35R69639Carbohydrate (chondroitin 4) sulfotransferase 11CHST1112q13.35T77351RotatinRTTN18q22.213.33AA203284Basic transcription factor 3BTF35q13.213.33AA056664V-akt murine thymoma viral oncogene homolog 1AKT114q32.32\|14q32.3213.31BE385427Chromatin modifying protein 6CHMP617q25.313.26BI850411CalnexinCANX5q3513.19BG687243Similar to ribosomal protein S13LOC7292361p32.313.16BE256276Ribosomal protein L32RPL323p25-p2413.15W17368Hexose-6-phosphate dehydrogenaseH6PD1p3613.04N56629Hypoxia upregulated 1HYOU111q23.1-q23.313.02R48663Nuclear factor of activated T-cells, cytoplasmicNFATC2IP16p11.212.98BQ052715Pyruvate kinase, musclePKM215q2212.97R02012Downstream neighbor of SONDONSON21q22.112.97AA203750Dimethylglycine dehydrogenaseDMGDH5q14.112.96AA058399Zinc finger protein 720ZNF72016p11.212.89H69509ATP-binding cassette, sub-family B (MDR/TAP)ABCB101q4212.86W20454Fibronectin 1FN12q3412.85N80357NDRG family member 2NDRG214q11.212.84W16514Rho family GTPase 1RND112q12-q1312.81AA021382Secreted protein, acidic, cysteine-rich (osteonectin)SPARC5q31.3-q3212.76H90355Ubiquitin protein ligase E3 component n-recognin 1UBR115q1312.67N44935B-cell receptor-associated protein 31BCAP31Xq2812.66AA054571Phosphatidylinositol glycan anchor biosynthesis, class VPIGV1p36.1112.65W61045Polymerase (DNA-directed), delta 4POLD411q1312.65R25725Cylindromatosis (turban tumor syndrome)CYLD16q12.112.63BM468576Chaperonin containing TCP1, subunit 6A (zeta 1)CCT6A7p11.212.61R55158V-ral simian leukemia viral oncogene homolog BRALB2cen-q1312.58N77205RAN binding protein 2RANBP22q12.312.55AA121350DCN1, defective in cullin neddylation 1DCUN1D213q3412.49H22871Peptidase DPEPD19q12-q13.212.41H71235Sialic acid binding Ig-like lectin 5SIGLEC519q13.312.41W25557Tripartite motif-containing 28TRIM2819q13.412.37H78781Absent in melanoma 1AIM16q2112.37N51173SpastinSPAST2p24-p2112.36AA001324TIMP metallopeptidase inhibitor 1TIMP1Xp11.3-p11.2312.34R16054HMG-box transcription factor 1HBP17q22-q3112.34R88469Dipeptidyl-peptidase 6DPP67q36.212.34AA037249ATP synthaseATP5C110p15.112.32T84763Cell division cycle associated 8CDCA81p34.312.30R69935Hypothetical protein FLJ10404FLJ104045q35.312.29H89836Phospholipase D1, phosphatidylcholine-specificPLD13q2612.28R48131SH3-domain binding protein 2SH3BP24p16.312.27AA007268Polyhomeotic homolog 2 (Drosophila)PHC21p34.312.19H52288Metallothionein 1EMT1E16q1312.18AA044796Similar to BMS1-like, ribosome assembly proteinLOC72909610q22.212.17T70535NUAK family, SNF1-like kinase, 1NUAK112q23.312.16BQ083501Ribosomal protein L12RPL129q3412.16H72796Hexose-6-phosphate dehydrogenaseH6PD1p3612.05N99693Chromosome 12 open reading frame 32C12orf3212p13.3312.05BQ063705Coiled-coil-helix-coiled-coil-helix domain containing 2CHCHD27p11.212.04AA040816Cleavage and polyadenylation specific factor 3, 73 kDaCPSF32p25.112.03R50700Mercaptopyruvate sulfurtransferaseMPST22q13.111.95H38879Phosphoserine phosphatasePSPH7p15.2-p15.111.93AA059211Male germ cell-associated kinaseMAK6p2411.93W21187Thymidylate synthetaseTYMS18p11.3211.92W49716GRAM domain containing 3GRAMD35q23.211.90W05242DEAD (Asp-Glu-Ala-Asp) box polypeptide 5DDX517q2111.90N28562Exportin, tRNA (nuclear export receptor for tRNAs)XPOT12q14.211.86AA128587Zinc finger protein 629ZNF62916p11.211.83N76529Membrane metallo-endopeptidaseMME3q25.1-q25.211.72N44807NF-kappaB activating proteinNKAPXq2411.67AA147560Hect domain and RLD 2 pseudogeneLOC44024815q13.111.67H62176E1A binding protein p300EP30022q13.211.65AA030048Protein kinase, cAMP-dependent, regulatory, type I, betaPRKAR1B7p2211.63R82429Alpha-methylacyl-CoA racemaseAMACR5p1311.63BM457262Non-metastatic cells 1, protein (NM23A) expressed inNME117q21.311.61W19413Cytoskeleton-associated protein 4CKAP412q23.311.59AA054778Homeobox A10HOXA107p15-p1411.58N36197Proline-rich protein HaeIII subfamily 1PRH112p13.211.57W47528Overexpressed in colon carcinoma-1OCC-112q23.311.54BM559619MOB1, Mps One Binder kinase activator-like 1B (yeast)MOBK1B2p13.111.53N46377Galactose-3-O-sulfotransferase 4GAL3ST47q22.111.53AA033651UDP-N-acetyl-alpha-D-galactosamineGALNT612q1311.50R97614Ribosomal protein L32 pseudogene 3RPL32P33q21.311.49H82707Protein phosphatase 2 (formerly 2A), regulatory subunit B'PPP2R3A3q22.111.48H16005Niemann-Pick disease, type C2NPC214q24.311.46R23610Zinc and ring finger 2ZNRF27p15.111.45H25541Ring finger protein 138RNF13818q12.111.44AA114919Y box binding protein 1YBX11p3411.43H57747Betaine-homocysteine methyltransferaseBHMT5q13.1-q1511.42BM974828Ribosomal protein L18RPL1819q1311.41H97422NOL1/NOP2/Sun domain family, member 3NSUN33q11.211.40BG545342Synaptojanin 1SYNJ121q22.211.40BE790941Centromere protein OCENPO2p23.311.36H66235Ataxin 2ATXN212q24.111.31H82010Transcription termination factor, RNA polymerase IITTF21p2211.30N40640WW domain binding protein 5WBP5Xq22.1-q22.211.27H21773Hypothetical protein LOC145758LOC14575815q26.311.25T97204Interleukin 6 receptorIL6R1q2111.22BQ050102Proteasome (prosome, macropain) subunit, beta type, 2PSMB21p34.211.22W02584Lysosomal trafficking regulatorLYST1q42.1-q42.211.06H61357Tumor protein p53 (Li-Fraumeni syndrome)TP5317p13.111.03N38855Cyclin B1 interacting protein 1CCNB1IP114q11.211.03BM928663Chromodomain helicase DNA binding protein 4CHD412p1311.01BM905720LSM12 homolog (S cerevisiae)LSM1217q21.3110.99H64813Ribosomal protein S28 pseudogeneLOC64619511q14.110.98AA058638ATPase, H + transporting, lysosomal 13 kDa, V1 subunit G1ATP6V1G19q3210.98BG469305Keratin 18KRT1812q1310.96T95392Microfibrillar-associated protein 3-likeMFAP3L4q32.310.91AA037600Regulator of chromosome condensation 1RCC11p36.110.90\* SAM assigns a score to each gene on the basis of a change in gene expression relative to the standard deviation of repeated measurements.Table 2Downregulated genesGenBankNameSymbolCytobandScore (d)\*BG700671Potassium inwardly rectifying channelKCNJ132q37−57.88H88081OtoraplinOTOR20p12.1-p11.23−55.73H81127Protein kinase, AMP-activatedPRKAB21q21.1−49.72H44375Myocyte enhancer factor 2BMEF2B19p12−45.98N48215Solute carrier family 20SLC20A12q11-q14−45.74AA099522MORC family CW-type zinc finger 4MORC4Xq22.3−45.56BE904276Protein tyrosine phosphatase, non-receptor type 3PTPN39q31−45.11H03729Epidermal growth factor receptorEGFR7p12−41.14T84537Fanconi anemia, complementation group D2FANCD23p26−41.10BG776239Wilms tumor 1WT111p13−38.77AA044149Methylmalonyl CoA epimeraseMCEE2p13.3−38.44BF437100Transmembrane protein 87BTMEM87B2q13−37.68AA010608ParvalbuminPVALB22q12-q13.1\|22q13.1−36.84BG818724Solute carrier family 7SLC7A113q12-q14−36.44AA156812Collagen, Type XVIII, alpha 1COL18A121q22.3−35.48N76723Hypothetical protein LOC150166LOC15016622q11.21−35.03N50000Methionine adenosyltransferase I, alphaMAT1A10q22−34.96AA136950Plexin domain containing 2PLXDC210p12.32-p12.31−34.86BG620850Chorionic somatomammotropin hormone 2CSH217q24.2−34.04H79911Core-binding factor, runt domainCBFA2T316q24−33.25N55596NOL1/NOP2/Sun domain family, member 7NSUN74p14−33.05W44535NeurochondrinNCDN1p34.3−33.00N42329Suppressor of cytokine signaling 6SOCS618q22.2−32.03AA127799FYVE and coiled-coil domain containing 1FYCO13p21.31−31.87BG622452ADAM metallopeptidase domain 12 (meltrin alpha)ADAM1210q26.3−31.86BQ073808Proteasome (prosome, macropain)PSMC419q13.11-q13.13−31.65BM466167Septin 6SEP6Xq24−31.55H52445Leucine rich repeat containing 31LRRC313q26.2−31.41W87840Helicase with zinc fingerHELZ17q24.2−29.81R53682SH2 domain containing 3CSH2D3C9q34.11−29.56H69334Pirin (iron-binding nuclear protein)PIRXp22.2−29.15W05657E74-like factor 1 (ets domain transcription factor)ELF113q13−28.60W47223Mitochondrial trans-2-enoyl-CoA reductaseMECR1p36.1-p35.1−28.59AA053903FRY-likeFRYL4p12−28.54N44611Transmembrane protein 50BTMEM50B21q22.11−28.28R99229Hydroxymethylbilane synthaseHMBS11q23.3−28.12BM857788Nuclear receptor co-repressor 2NCOR212q24−27.72N52672Nuclear receptor subfamily 1, group D, member 2NR1D23p24.2−27.52H17037Similar to CG4502-PAFLJ250765p15.31−26.95BE779318Transcription elongation factor B (SIII)TCEB31p36.1−26.77T90862Remodeling and spacing factor 1RSF111q14.1−26.74AA455435Chromosome 9 open reading frame 5C9orf59q31−26.67AI188464Matrix metallopeptidase 11 (stromelysin 3)MMP1122q11.2\|22q11.23−26.36N54724Chromosome 14 open reading frame 24C14orf2414q13.2−26.14W38932Heme oxygenase (decycling) 2HMOX216p13.3−25.94N51855Poly (ADP-ribose) polymerase family, member 2PARP214q11.2-q12−25.87R99225Keratin associated protein 4-7KRTAP4-717q12-q21−25.75T78280Histone acetyltransferase 1HAT12q31.2-q33.1−24.75R16431Chromosome 4 open reading frame 29C4orf294q28.2−24.61H91396Bile acid coenzyme A: amino acid N-acyltransferaseBAAT9q22.3−24.49T66756Sprouty homolog 3 (Drosophila)SPRY3Xq28 and Yq12−24.16BG565707Fibrinogen gamma chainFGG4q28−24.00AA031920Cytochrome b-245, alpha polypeptideCYBA16q24−23.63H77390Golgi autoantigen, golgin subfamily a, 1GOLGA19q33.3−23.34R98300KIAA0286 proteinKIAA028612q13.3−23.28H25352Serum response factor binding protein 1SRFBP15q23.1−22.98H67225Solute carrier family 7SLC7A28p22-p21.3−22.56AA151360Rho GTPase activating protein 12ARHGAP1210q11.1−22.36N34285Solute carrier family 26SLC26A25q31-q34−22.34H59530CHK1 checkpoint homolog (S pombe)CHEK111q24-q24−22.25H68793Yip1 interacting factor homolog B (S cerevisiae)YIF1B19q13.2−22.09H75715Membrane bound O-acyltransferase domain containing 2MBOAT22p25.1−21.77W19459Dipeptidyl-peptidase 8DPP815q22−21.59R61012CDC42 binding protein kinase alpha (DMPK-like)CDC42BPA1q42.11−21.38H61387Reticulon 4 receptorRTN4R22q11.21−21.33H28872Aspartyl-tRNA synthetaseDARS2q21.3−21.21W47361Folate receptor 3 (gamma)FOLR311q13−21.16T92079Proteasome (prosome, macropain) activator subunit 2PSME214q11.2−21.15N55035Peroxisomal biogenesis factor 3PEX36q23-q24−21.03N48524TIA1 cytotoxic granule-associated RNA binding protein-like 1TIAL110q−20.94BG770889RAB11 family interacting protein 2 (class I)RAB11FIP210q26.11−20.75H97449Integrin, beta 5ITGB53q21.2−20.71T78739EPH receptor B2EPHB21p36.1-p35−20.62H10896Dual specificity phosphatase 4DUSP48p12-p11−20.42T87012CD79a molecule, immunoglobulin-associated alphaCD79A19q13.2−20.31W16524CDC42 binding protein kinase alpha (DMPK-like)CDC42BPA1q42.11−20.30R47766Transient receptor potential cation channel, subfamily CTRPC4AP20q11.22−20.23T64848Period homolog 3 (Drosophila)PER31p36.23−20.16N54874Chromosome 20 open reading frame 39C20orf3920p11.21−20.16T95182Chromosome 6 open reading frame 86C6orf866p25.2−20.14BM994830UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferaseB4GALT19p13−19.97N44094Cyclin JCCNJ10pter-q26.12−19.77R02669Adaptor-related protein complex 3, beta 1 subunitAP3B15q14.1−19.77H00518Multiple inositol polyphosphate histidine phosphatase, 1MINPP110q23−19.73R64061Pregnancy specific beta-1-glycoprotein 5PSG519q13.2−19.62T84786TRNA splicing endonuclease 2 homolog (S cerevisiae)TSEN23p25.1−19.50BI818657Serine/threonine kinase 10STK105q35.1−19.49H79636KIAA1012KIAA101218q12.1−19.41AA055329Hypothetical locus LOC678655LOC67865512p13.31−19.28H80810Formin-like 2FMNL22q23.3−19.26R91604Solute carrier family 38, member 2SLC38A212q−19.21T77428ELOVL family member 5, elongation of long chain fatty acidsELOVL56p21.1-p12.1−19.17H85608Protein phosphatase 1, regulatory (inhibitor) subunit 2PPP1R23q29−19.08T98709Major facilitator superfamily domain containing 11MFSD1117q25−19.04AA033653Major histocompatibility complex, class II, DR beta 1HLA-DRB16p21.3−19.03W78787Complement component 5C59q33-q34−19.01AA001996MutS homolog 6 (E coli)MSH62p16−18.87N32361PQ loop repeat containing 3PQLC32p25.1−18.85H45525Ras homolog gene family, member G (rho G)RHOG11p15.5-p15.4−18.79AI927909Homogentisate 1,2-dioxygenase (homogentisate oxidase)HGD3q13.33−18.75R05896Sodium channel modifier 1SCNM11q21.2−18.59N80988GTP binding protein 2GTPBP26p21-p12−18.53N40600SUMO1/sentrin specific peptidase 7SENP73q12−18.47R23473PAK1 interacting protein 1PAK1IP16p24.2−18.40BQ063621Calsyntenin 1CLSTN11p36.22−18.36H58311Coagulation factor V (proaccelerin, labile factor)F51q23−18.29H08311DTW domain containing 2DTWD25q23.1−18.26W02106Solute carrier family 26 (sulfate transporter), member 2SLC26A25q31-q34−18.22H391621-acylglycerol-3-phosphate O-acyltransferase 1AGPAT16p21.3−17.90AI368607Family with sequence similarity 13, member A1FAM13A14q22.1−17.89AA040364Hypothetical protein LOC284513LOC2845131p36.13−17.84H38322SET binding factor 1SBF122q13.33−17.69R73417Peptidase inhibitor 16PI166p21.2−17.60T67154IMP2 inner mitochondrial membrane peptidase-likeIMMP2L7q31−17.45R96767Phospholipase C, beta 4PLCB420p12−17.42N35681Diablo homolog (Drosophila)DIABLO12q24.31−17.29W25288SNAP-associated proteinSNAPAP1q21.3−17.27AA203442Chromosome 9 open reading frame 39C9orf399p22.2−17.21R73337Zinc finger protein 777ZNF7777q36.1−17.08N73236Storkhead box 1STOX110q21.3−16.94H39156Myotubularin related protein 6MTMR613q12−16.93T77015GSG1-likeGSG1L16p11.2−16.66R23489Zinc finger protein 354AZNF354A5q35.3−16.62H64555S100 calcium binding protein A2S100A21q21−16.52W90519Zinc finger protein 652ZNF65217q21.32−16.50W19130Plexin A2PLXNA21q32.2−16.39H78273Sperm associated antigen 9SPAG917q21.33−16.33AA156879Zinc finger protein 615ZNF61519q13.33−16.30N53192Hypothetical protein MGC22014hCG_407382p13.1−16.00BG682138Secreted protein, acidic, cysteine-rich (osteonectin)SPARC5q31.3-q32−15.87H41974Integrin, alpha 3ITGA317q21.33−15.84H79050Protein tyrosine phosphatase, receptor type, EPTPRE10q26−15.83W48559Zinc finger, MYM-type 1ZMYM11p34.3−15.78H87048ADP-ribosylation factor GTPase activating protein 3ARFGAP322q13.2-q13.3−15.76T84174Eukaryotic translation initiation factor 3EIF3S97p22.2−15.76N40120Zinc finger protein 33BZNF33B10q11.2−15.74W35313Sterile alpha motif and leucine zipper containing kinase AZKZAK2q24.2−15.70AA040656Zinc finger protein 502ZNF5023p21.31−15.70H18810Importin 8IPO812p11.21−15.68R12736Staufen, RNA binding protein, homolog 2 (Drosophila)STAU28q13-q21.1−15.61N74741BTG family, member 3BTG321q21.1-q21.2−15.61AA069533Chromosome 7 open reading frame 42C7orf427q11.21−15.55N28267Integrin, alpha XITGAX16p11.2−15.47AA135718Neuropilin 1NRP110p12−15.46R50902Tubulin, gamma complex associated protein 6TUBGCP622q13.31-q13.33−15.46BQ020504Translocase of outer mitochondrial membrane 20 homologTOMM201q42−15.43BM545369Hect domain and RLD 2 pseudogene 2HERC2P215q11.2−15.39W58640SECIS binding protein 2SECISBP29q22.2−15.21W49512Bradykinin receptor B1BDKRB114q32.1-q32.2−15.19N46282PiggyBac transposable element derived 2PGBD21q44−15.12W31642Early B-cell factor 3EBF310q26.3−15.05BG623586ADAM metallopeptidase with thrombospondin type 1 motifADAMTS521q21.3−14.97W87709Kelch-like 23 (Drosophila)KLHL232q31.1−14.97N44005EF-hand calcium binding domain 2EFCAB21q44−14.96W52509ARV1 homolog (S cerevisiae)ARV11q42.2−14.95H79753Death-associated proteinDAP5p15.2−14.93BI905854Glycerophosphodiester phosphodiesterase domain containing 3GDPD316p11.2−14.71H53660HLA-B associated transcript 3BAT36p21.3−14.71AA037312ATP synthase mitochondrial F1 complex assembly factor 1ATPAF11p33-p32.3−14.68N57425DAZ associated protein 2DAZAP212q12−14.67BM545099Lectin, galactoside-binding, soluble, 9 (galectin 9)LGALS917q11.1−14.66W16685N-glycanase 1NGLY13p24.2−14.64N76853Golgi autoantigen, golgin subfamily b, macrogolginGOLGB13q13−14.59AA001311Hypothetical protein LOC129293LOC1292932p11.2−14.54W40439Forkhead box J1FOXJ117q22-q25−14.44H61030REX2, RNA exonuclease 2 homolog (S cerevisiae)REXO211q23.1-q23.2−14.39H03728G1 to S phase transition 1GSPT116p13.1−14.37W48584Procollagen-proline, 2-oxoglutarate 4-dioxygenaseP4HA25q31−14.30BI861012Mannosidase, alpha, class 1B, member 1MAN1B19q34−14.24AA203133DNA (cytosine-5-)-methyltransferase 1DNMT119p13.2−14.15AA481714Chromosome 6 open reading frame 62C6orf626p22.2−14.02H08319Zinc finger protein 783ZNF7837q36.1−14.01N441423-hydroxy-3-methylglutaryl-coenzyme A reductaseHMGCR5q13.3-q14−13.97R15789Tumor suppressing subtransferable candidate 1TSSC12p25.3−13.97H79770Tripartite motif-containing 27TRIM276p22−13.93AI056197Amidohydrolase domain containing 2AMDHD216p13.3−13.92BE871226TAF6 RNA polymerase IITAF67q22.1−13.87BM468475Keratin 8 pseudogene 12KRT8P123q26.1−13.84H10533Plasminogen activator, tissuePLAT8p12−13.82H93653Collagen-like tail subunit of asymmetric acetylcholinesteraseCOLQ3p25−13.82BG333273CD47 moleculeCD473q13.1-q13.2−13.80H44717Cytochrome c oxidase subunit 8A (ubiquitous)COX8A11q12-q13−13.79W38526Exostoses (multiple)-like 2EXTL21p21−13.75R86053Nuclear factor of kappa light polypeptide gene enhancerNFKB210q24−13.71AA203387Trophinin associated protein (tastin)TROAP12q13.12−13.70H52351Transmembrane protein 150TMEM1502p11.2−13.70W47015Ts translation elongation factor, mitochondrialTSFM12q13-q14−13.60T89583Spermatogenesis associated 21SPATA211p36.13−13.59BM993318Ubiquitin specific peptidase 24USP241p32.3−13.58W88434Carboxypeptidase B2 (plasma)CPB213q14.11−13.55N48417GA binding protein transcription factor, alpha subunit 60 kDaGABPA21q21-q22.1\|21q21.3−13.53H81801Phosphatidylinositol 3,4,5-trisphosphate-dependent RAC exchanger 1PREX120q13.13−13.52AI478910FERM domain containing 6FRMD614q22.1−13.45AA450143WD repeat domain 27WDR276q27−13.41H61757ELK4, ETS-domain protein (SRF accessory protein 1)ELK41q32−13.31BM459914Serine/threonine kinase 4STK420q11.2-q13.2−13.31W60673CREB regulated transcription coactivator 3CRTC315q26.1−13.28R32668Component of oligomeric golgi complex 3COG313q14.12−13.27AA045300CDC42 small effector 2CDC42SE25q31.1−13.17W56454Furin (paired basic amino acid cleaving enzyme)FURIN15q26.1−13.12W61099Chromosome X open reading frame 36CXorf36 −13.06AA037834Methylmalonic aciduria (cobalamin deficiency) cblB typeMMAB12q24−13.06W90717Solute carrier family 24 (sodium/potassium/calcium exchanger)SLC24A414q32.12−13.05N44262Pecanex homolog (Drosophila)PCNX14q24.2−12.99T70417REC8 homolog (yeast)REC814q11.2-q12−12.98BE899110Family with sequence similarity 105, member BFAM105B5p15.2−12.94R06564UDP-galactose-4-epimeraseGALE1p36-p35−12.92R50922Neuroligin 4, X-linkedNLGN4XXp22.32-p22.31−12.89H15612COX10 homolog, cytochrome c oxidase assembly proteinCOX1017p12-p11.2−12.88R18433Opioid binding protein/cell adhesion molecule-likeOPCML11q25−12.85AA143060Melanoma associated antigen (mutated) 1MUM119p13.3−12.81BF969700Chromosome 12 open reading frame 35C12orf3512p11.21−12.79N43949Mitogen-activated protein kinase kinase kinase kinase 4MAP4K42q11.2-q12−12.77N71526Inhibitor of kappa light polypeptide gene enhancer in B-cellsIKBKB8p11.2−12.73W78799Nudix (nucleoside diphosphate linked moiety X)-type motif 13NUDT1310q22.1−12.69W20458Tripartite motif-containing 59TRIM593q26.1−12.69H89618WNK lysine deficient protein kinase 1WNK112p13.3−12.67R65820SLC2A4 regulatorSLC2A4RG20q13.33−12.61R87913Potassium voltage-gated channel, delayed-rectifier, subfamily SKCNS120q12−12.60N57603Solute carrier organic anion transporter family, member 1C1SLCO1C112p12.2−12.55AA045905Forkhead box P1FOXP13p14.1−12.55H29349Abelson helper integration site 1AHI16q23.3−12.54H08988Ubiquitin specific peptidase 7 (herpes virus-associated)USP716p13.3−12.43R23677Nucleolar protein 4NOL418q12−12.43H46899Adenosine deaminase, RNA-specific, B2 (RED2 homolog rat)ADARB210p15.3−12.41BI667959Reticulon 1RTN114q23.1−12.39BG323782Coiled-coil domain containing 14CCDC143q21.1−12.36R38905Dihydropyrimidinase-like 5DPYSL52p23.3−12.35N23456CytoglobinCYGB17q25.3−12.34R11685COP9 constitutive photomorphogenic homolog subunit 5COPS58q13.2−12.33R06410O-6-methylguanine-DNA methyltransferaseMGMT10q26−12.31H63698N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase DNAPE-PLD7q22.1−12.27H93191Ubiquitin specific peptidase 3USP315q22.3−12.26AA069502Hypothetical protein DKFZp434H1419DKFZp434H14192q35−12.24AA043530MORN repeat containing 2MORN22p22.1−12.21N57339LMBR1 domain containing 1LMBRD16q13−12.20H40732PPAR binding proteinPPARBP17q12-q21.1−12.19AI822112Similar to SR protein related family member (rsr-1)LOC7286761q42.13−12.18R12743HECT domain containing 1HECTD114q12−12.14N48445RAB33A, member RAS oncogene familyRAB33AXq25−12.13H03305Bromodomain containing 1BRD122q13.33−12.13AA010089Hypothetical protein LOC157860LOC1578608p11.23−12.09H931766-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3PFKFB310p14-p15−12.07R12649Solute carrier family 13 (sodium-dependent dicarboxylate transporter)SLC13A320q12-q13.1−12.05R14154Hypothetical protein LOC286063LOC2860638q11.21−12.03R61444Thyroid adenoma associatedTHADA2p21−12.02W17278Solute carrier family 25 (mitochondrial oxodicarboxylate carrier)SLC25A2114q11.2−12.00T77303Leucine-rich repeat LGI family, member 2LGI24p15.2−11.98AA043837Coiled-coil domain containing 45CCDC4517q24.1−11.93R52735THAP domain containing 8THAP819q13.12−11.92W46207UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1B4GALT19p13−11.79BI914695Immunoglobulin superfamily containing leucine-rich repeat 2ISLR215q24.1−11.78BQ000722Deoxyribonuclease I-like 1DNASE1L1Xq28−11.73N52657MYC binding protein 2MYCBP213q22−11.68AI340082Sulfotransferase family 1E, estrogen-preferring, member 1SULT1E14q13.1−11.67N54717Acyl-coenzyme A binding domain containing 5ACBD510p12.1−11.67R16400Elongation factor, RNA polymerase II, 2ELL25q15−11.63AA151264ALS2 C-terminal likeALS2CL3p21.31−11.59T80372Calcium channel, voltage-dependent, alpha 2/delta subunit 2CACNA2D23p21.3−11.58AW872398AmphiphysinAMPH7p14-p13−11.53H08101Glutaminase 2 (liver, mitochondrial)GLS212q13−11.51AA134026Ubiquitin-conjugating enzyme E2A (RAD6 homolog)UBE2AXq24-q25−11.49R72472HLA-B associated transcript 1BAT16p21.3−11.47BM450631Heat shock protein 90 kDa alpha (cytosolic), class A member 2HSP90AA211p14.1−11.45AA534429Chromosome 1 open reading frame 38C1orf381p35.3−11.44BI753390Amyloid beta (A4) precursor protein-binding, family AAPBA215q11-q12−11.44BF112255Tousled-like kinase 2TLK217q23−11.42T78737KIAA2026KIAA20269p24.1−11.42R39428Protein tyrosine phosphatase, receptor type, GPTPRG3p21-p14−11.40N42943PHD finger protein 17PHF174q26-q27−11.38H86918Pleckstrin homology domain containing, family B (evectins)PLEKHB111q13.5-q14.1−11.38R23434Membrane-bound transcription factor peptidase, site 2MBTPS2Xp22.1-p22.2−11.37R17293GLE1 RNA export mediator-like (yeast)GLE1L9q34.11−11.33BI522504Zinc finger protein 605ZNF60512q24.33−11.29AA056151SEC24 related gene family, member C (S. cerevisiae)SEC24C10q22.2−11.28AA055164Low density lipoprotein receptor-related protein 6LRP612p11-p13−11.21R27647KIAA1333KIAA133314q12−11.18\* SAM assigns a score to each gene on the basis of a change in gene expression relative to the standard deviation of repeated measurements.Table 3Main upregulated genes related to bone formationGeneFunctionEffectReferenceSTAT 3Transcriptional factor, activation of the MAP kinaseBone turnoverItoh et al. \[[@CR27]\]HOXA 10Activation of Runx2, alkaline phosphatase, osteocalcin, and bone sialoproteinOsteogenic responseHassan et al. \[[@CR25]\]AKT1Suppression of osteoblasts apoptosis through inhibition of Fox03a and Bim; Mediation of the osteoblastic bone formation by IGF-1 and insulin.Bone formationKawamura et al. \[[@CR29]\]CALM1Signal transduction, stimuli to proliferationBone formationRhymer et al. \[[@CR40]\]P2RX7Activation of P2RX7 receptors stimulates expression of osteoblast markers and enhances mineralization in cultures cellsPromote osteogenesisOhlendorff et al. \[[@CR37]\]FN1Adhesion and migration cellular processExtracellular matrix stability; tissue healingPotts and Campbell \[[@CR39]\]COL1A2Collagen 1α2, chain of the most abundant collagen in the human organismExtracellular matrix stabilityAntoniv et al. \[[@CR6]\]SPARCThe most abundant noncollagenous protein in the bone tissue.Modulation of the cell-matrix interaction and production of the matrixYan and Sage \[[@CR47]\]VCLAssociated with the intercellular junctions between the cells and the matrixAnchorages the actin to the cellular membraneZiegler et al. \[[@CR49]\]TIMP1Inhibits collagen and other components of extracellular matrix degradation operated by the metalloproteinaseDecrease matrix degradationHatori et al. \[[@CR26]\]Table 4Main downregulated genes related to bone formationGeneFunctionEffectReferenceMMP-11Metallopeptidase with substrate specificity, including proteoglycans, lamini, and fibronectinDegradation of extracellular matrixMatziari et al. \[[@CR35]\]DUSP4Inactivates the superfamily of MAP kinaseInhibition of proliferation and differentiationCaunt et al. \[[@CR17]\]

In particular, PEMFs induced upregulation of several genes at the transcriptional level like STAT3, homeobox A10 (HOXA10), and V-akt murine thymoma viral oncogene homolog 1 (AKT1). Some genes acting at the transductional level also are upregulated including calmodulin (CALM1), activator protein 1 (AP-1), Nuclear factor kappaB (NF-KB), cAMP response element binding (CREB), and P2RX7 (Table [3](#Tab3){ref-type="table"}). Several interesting overexpressed genes are components of cytoskeleton and involved in cell adhesion (Table [3](#Tab3){ref-type="table"}). Examples are fibronectin (FN1) and vinculin (VCL). PEMF also increased the expression of genes encoding for collagenous and noncollagenous extracellular matrix proteins including collagen Type 1α2 (COL1A2), osteonectin (SPARC), and metallopeptidase inhibitor 1 (TIMP1) (Table [3](#Tab3){ref-type="table"}).

Some genes downregulated by PEMFs are related to degradation of extracellular matrix (ECM) (Table [4](#Tab4){ref-type="table"}), specifically, matrix metallopeptidase 11 (MMP11), or stromelysin 3 and dual specificity phosphatase 4 (DUSP4).

Discussion {#Sec4}
==========

The improvement of osteogenesis is important because of the wide clinical applications it may have. PEMFs reportedly restart osteogenesis in disorders in which it has stopped \[[@CR34]\] and in disorders in which osteogenesis needs to be enhanced \[[@CR32]\]. Although considerable basic and clinical research on PEMFs has been reported, their mechanism of action is not completely clear. Moreover, studies in the existing literature have so far focused only on a few aspects of cell activities \[[@CR9], [@CR10], [@CR46]\], or they have been performed by using different types of signals in different experimental conditions \[[@CR1], [@CR9], [@CR22], [@CR23]\]. To address these limitations in the literature, we asked (1) whether PEMFs affected a wide array of genes in human osteoblastlike cells (MG63), and (2) whether and to what extent PEMFs induce proliferation and differentiation of osteoblasts.

We acknowledge several limitations. First, the experiment was performed using a human osteosarcoma cell line (MG63), whereas the use of a primary human osteoblast cell culture might better replicate what happens in humans in vivo. We chose the MG63 cell line because these cells show a phenotype similar to that of normal human osteoblasts, while also providing a reproducible experimental model suitable for the microarray analysis. Second, as it is still difficult to explain the roles of all genes, whose expression was modified, we focused on the role of genes with well-known functions related to osteogenesis. Third, although microarray technology is widely accepted as a valid approach to describe changes induced by a factor on cell environment, additional research using, for example RT-PCR, might be useful to provide supplementary support for the results obtained. Fourth, we studied responses at only one time. We chose 18 hours exposure time on the basis of a previous time experiment, in which a peak in DNA synthesis was seen after 18 hours of stimulation in MG63 cultures maintained in the presence of 10% FCS \[[@CR45]\]. In contrast, Lohmann et al. reported PEMFs enhanced cell differentiation in MG63 cultures and reduced cell proliferation \[[@CR30]\]. The differences existing between the two sets of data regarding cell proliferation could be related to the different experimental conditions used. Lohmann et al. exposed MG63 cultures when they reached confluence. When cultures are confluent they stop to proliferate. We exposed cells to PEMF when cultures were subconfluent, therefore, they responded with an enhancement of proliferation. We cannot extrapolate our findings to shorter or longer exposures to PEMFs.

PEMFs appear to act on bone formation by inducing upregulation of several genes related to osteoblast proliferation and differentiation. Among those genes, HOXA10, a transcriptional factor that acts positively on RUNX2, is the main transcriptional regulator of osteoblast differentiation \[[@CR25]\]. HOXA10 controls osteoblastogenesis via RUNX2-promoted osteoprogenitor cell differentiation in immature osteoblasts \[[@CR25]\]. This protein also is believed to be involved in activation of alkaline phosphatase, osteocalcin, and sialoprotein genes \[[@CR25]\]. We also observed STAT3, P2RX7, and AKT1 upregulation. It has been suggested that osteoblast-specific disruption of STAT3 results in an osteopenic phenotype \[[@CR27], [@CR41]\]. STAT3, involved in bone turnover \[[@CR27]\], regulates the transcription of various genes that modulate cell proliferation and differentiation in a cell-specific manner \[[@CR27]\]. P2RX7 is a purinergic receptor, which is correlated with calcium channels and interacts with the calmodulin-dependent protein \[[@CR37]\]. Activation of P2RX7 receptors by exogenous nucleotides stimulates expression of osteoblast markers and enhances mineralization in cultures of rat calvarial cells promoting osteogenesis \[[@CR37]\]. V-akt murine thymoma viral oncogene homolog 1 (AKT1), is a phosphoinositide-dependent serine-threonine protein kinase, and one of the key players in the signaling of potent bone anabolic factors \[[@CR29]\]. The disruption of AKT1 in mice led to low-turnover osteopenia through dysfunction \[[@CR29]\]. AKT1 deficiency causes decreased bone mass and formation \[[@CR29]\], impairs RUNX2-dependent differentiation and function of osteoblasts \[[@CR29]\], and impairs bone resorption via dysfunction of osteoblasts and osteoclasts \[[@CR29]\]. AKT1 suppresses osteoblasts apoptosis through inhibition of FOXO3a and Bim \[[@CR29]\], and may mediate the osteoblastic bone formation by IGF-1 \[[@CR29]\]. The IGF-1/AKT1 pathway might be a common pathway for bone anabolic action of parathyroid, thyroid, and growth hormone \[[@CR29]\].

We also observed upregulation of genes involved in connective and bone tissue formation (COL1A2) and noncollagenous extracellular matrix (ECM) synthesis (SPARC, FN1, VCL). COL1A2 encodes for collagen Type 1α2. Collagen Type 1 is the most represented collagen in the human organism and is important for ECM stability \[[@CR6]\]. Osteonectin (SPARC), the most abundant noncollagenous protein in bone tissue, modulates cell-matrix interaction and is involved in the tissue-remodeling process \[[@CR47]\]. FN1 is important for ECM stability and involved in adhesion and migration cellular processes such as tissue healing \[[@CR39]\]. VCL is a cytoskeletal protein associated with the intercellular junctions between the cells and the matrix \[[@CR49]\].

The effect of TIMP1 upregulation and of MMP-11 and DUSP4 downregulation can be interpreted as a decrease in the degradation process. TIMP1 promotes apposition of ECM by inhibiting collagen and other components of ECM degradation operated by the metalloproteinase \[[@CR26]\]. DUSP4 inactivates the superfamily of MAP kinase, which is involved with proliferation and differentiation. DUSP4 downregulation, then, stimulates proliferation \[[@CR17]\]. MMPs potentially can degrade almost all components of the periprosthetic ECM and contribute to prosthetic loosening and osteolysis through pathologic ECM degradation and bone remodeling around prostheses \[[@CR28], [@CR35]\]. The stromelysins especially have broad substrate specificity, including proteoglycans, laminin, and fibronectin \[[@CR35]\]. Stromelysin-1 determines the release and activation ECM-bound latent TGF-ß1 and is involved with ECM turnover \[[@CR8]\]. Upregulation of CALM1 promotes enhancement of calmodulin1, a protein involved in proliferative cell activation \[[@CR40]\]. Calmodulin also is involved in the transduction mechanism of PEMFs \[[@CR9]\].

Our data suggest many effects of PEMFs on human osteoblastlike cells in vitro. PEMFs seem to exert an anabolic effect on cells. In particular, they are consistent with abundant preclinical and clinical findings showing a positive effect of PEMFs on osteogenesis. Stimulation by PEMFs induces bone healing in patients, shortens the time of healing processes, and stimulates healing of nonunions. Exposure to PEMFs acts on cell behavior in different ways. More specifically, PEMFs stimulate cell proliferation and induce osteoblastogenesis and differentiation of osteoblasts. Moreover, PEMFs promote ECM apposition and mineralization, and decrease degradation and absorption processes of ECM. These data suggest a more comprehensive explanation of the observed clinical effect of PEMFs on the induction of osteogenesis. Given their broad effects, PEMFs might be useful in other fields such as regenerative medicine.
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